Brief: Nanexa 30 Mg Nex-22 Shows 36-Day Exposure Without Significant GI Side Effects
24/06/2025 07:06
June 24 (Reuters) - Nanexa AB NANEXA.ST: PRESENTS ONCE-MONTHLY LIRAGLUTIDE STUDY AT ADA SCIENTIFIC SESSIONS 30 MG NEX-22 SHOWS 36-DAY EXPOSURE WITHOUT SIGNIFICANT GI SIDE EFFECTS Source text: ID:nMFN6FDskJ Further company coverage: NANEXA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Nanexa AB
See all newsNanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
Brief: Nanexa And Novo Enter Global License, Collaboration Deal
Brief: Forge Nano And Nanexa To Develop Gmp-Compatible Ald Manufacturing Equipment
Brief: Nanexa Q2 Revenue Amounted To SEK 1.7 Million
Sweden's Nanexa Q1 revenue falls, loss widens